Transcenta Holding Limited

SEHK:6628 Stock Report

Market Cap: HK$311.7m

Transcenta Holding Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Xueming Qian

Chief executive officer

CN¥5.6m

Total compensation

CEO salary percentage20.3%
CEO tenure12.1yrs
CEO ownership12.7%
Management average tenure2.8yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15
Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

CEO Compensation Analysis

How has Xueming Qian's remuneration changed compared to Transcenta Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥359m

Mar 31 2024n/an/a

-CN¥411m

Dec 31 2023CN¥6mCN¥1m

-CN¥463m

Sep 30 2023n/an/a

-CN¥451m

Jun 30 2023n/an/a

-CN¥440m

Mar 31 2023n/an/a

-CN¥424m

Dec 31 2022CN¥6mCN¥1m

-CN¥407m

Sep 30 2022n/an/a

-CN¥666m

Jun 30 2022n/an/a

-CN¥925m

Mar 31 2022n/an/a

-CN¥2b

Dec 31 2021CN¥5mCN¥1m

-CN¥2b

Sep 30 2021n/an/a

-CN¥1b

Jun 30 2021n/an/a

-CN¥1b

Mar 31 2021n/an/a

-CN¥364m

Dec 31 2020CN¥51mCN¥1m

-CN¥317m

Dec 31 2019CN¥14mCN¥823k

-CN¥395m

Compensation vs Market: Xueming's total compensation ($USD767.65K) is above average for companies of similar size in the Hong Kong market ($USD232.96K).

Compensation vs Earnings: Xueming's compensation has been consistent with company performance over the past year.

CEO

Xueming Qian (55 yo)

12.1yrs

Tenure

CN¥5,562,000

Compensation

Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited and serves as its Chairman since June 07, 2024. He was the Founder, Chairman and Chief Executiv...

Leadership Team

NamePositionTenureCompensationOwnership
Xueming Qian
CEO & Executive Chairmanno dataCN¥5.56m12.72%
HK$ 39.7m
Xiaolu Weng
Executive VP & CFO2.9yrsCN¥8.32mno data
Christopher Hwang
Executive VP of Process Development & CTO5.8yrsno datano data
Wei Wang
VP of Investor Relations & Capital Markets Department and Secretary to the Board2.7yrsno datano data
Yi Gu
Senior VP & Head of Research5.8yrsno datano data
Charlie Qi
Senior Vice President of Global Clinical Development1.8yrsno datano data
Xichen Zhang
Senior Vice President of Manufacturing & Quality2.8yrsno datano data
Wen-I Chang
Senior Vice President of Oncology Franchise Strategy2.6yrsno datano data
Caroline Germa
Executive VP of Global Medicine Development & Chief Medical Officer2.3yrsno datano data
Kwan Wai Leung
Company Secretary3.4yrsno datano data

2.8yrs

Average Tenure

52yo

Average Age

Experienced Management: 6628's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Xueming Qian
CEO & Executive Chairman12.1yrsCN¥5.56m12.72%
HK$ 39.7m
Briggs W. Morrison
Chairman of Scientific Advisory Boardno datano datano data
Pasi Antero Janne
Member of Scientific Advisory Boardno datano datano data
Kumar Srinivasan
Independent Non-Executive Director1.9yrsCN¥226.00kno data
Ling Su
Member of Scientific Advisory Boardno datano datano data
Wei Chen
Independent Non-Executive Director1.3yrsCN¥72.00kno data
Susan M. Jerian
Member of Scientific Advisory Boardno datano datano data
Li Xu
Member of Scientific Advisory Board3.8yrsno data0.18%
HK$ 554.2k
Jiasong Tang
Independent Non-Executive Director3.2yrsCN¥219.00kno data
Zhihua Zhang
Independent Non-Executive Director3.2yrsCN¥219.00kno data

3.2yrs

Average Tenure

56yo

Average Age

Experienced Board: 6628's board of directors are considered experienced (3.2 years average tenure).